11 October 2021
Visiongain has published a new report entitled the Clinical Trial Supplies Market Report 2021-2031: Forecasts by Location (Offshore Clinical Site, Domestic Clinical Site), by Type (Small Molecule Products, Biologic Products, Medical Devices), by Services (Manufacturing, Packaging, Labelling, & Blinding, Logistics & Distribution, Storage & Retention, Comparator Sourcing), by Therapeutic Areas (Oncology, CNS & Mental Disorders, Digestive Disorders, Immunology Disease, Blood Disorders, Metabolic Disorders, Infectious Disease, Cardiovascular Disease (CVD), Others), by Phase (Phase-I, Phase-II, Phase-III, Phase-IV), by End-User (CROs, Pharma & Biotech Companies, Medical Device Companies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
How has COVID-19 had a significant negative impact on the Clinical Trial Supplies Market?
The COVID-19 pandemic has put a significant pressure on the clinical research business and is expected to have an impact on critical study outcomes; these effects must be evaluated during data analysis and interpretation. Nonetheless, the pandemic reaction has resulted in improvements that will improve the conduct of clinical research. There is an unmistakable need to reduce patient risks and facilitate their inclusion in clinical investigations. To respond to this new paradigm, innovation, flexibility, and judicious use of existing, available technologies will be critical.
Beyond COVID-19, sponsors will be trying to significantly accelerate patient recruiting and enrolment in order to make up for lost time. The future of clinical trials is changing, and in addition to scientific breakthroughs, the COVID-19 pandemic has highlighted an urgent need for clinical trials powered by next-generation technologies. Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology. Virtual trials are showing an extraordinary possibility for pharma and healthcare, elevating clinical trial management to a new level. Beyond COVID-19, it is expected that digital healthcare and virtual trials would become more widespread as part of the new "normal."
How this Report Will Benefit you?
Visiongain’s 575-page report provides 365 tables and 351 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global clinical trial supplies market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Clinical Trial Supplies. Get the financial analysis of the overall market and different segments including type, location, services, end-user, phase and capture higher market share. We believe that high opportunity remains in this fast-growing clinical trial supplies market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the current market drivers?
Integrated Services, Facilities, And Technology Development
In order to keep clinical trials going forward and prevent delays in medicines for patients who can benefit from them, supply and logistics sector, as well as pharma- and biotech businesses which work with other site solutions and more innovative techniques are vital. This is the first time that traditional onsite clinical trials have been disrupted around the world due to a pandemic. The United States Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the European Medicines Agency (EMA) are among the countries involved.
Considerations for the Cold Chain
Distribution facilities and managers need to provide in-house supply chain information in real time to assure patient safety and continuous dosing regimens in the whole research. Facilities must also support temperature-controlled storage at several temperature levels, including ambient, regulated, cooled, frozen and depth frozen temperatures. A key element of the biopharmaceutical mix is the cold chain. The effectively managed technique is of paramount importance for maintaining product safety and stability, and hence product safety. While this applies to commercial pharmaceuticals, the problem with clinical trial materials is particularly critical. Stage two should include a supplier audit, and in addition to regular business terms, followed by the implementation of quality technical agreements.
Where are the market opportunities?
Integration of Technical Solutions
A good system of clinical trial supply chain management involves the tracking of returns, reconciliation and destruction. At the beginning of the study with the integration of technical solutions the return and destruction process should be defined. Best practise benefits from interactive responses systems for supply chain management, reduction of storage and dosing failures, numerous expiry times, ultimate reconciliation, recycling and disposal. The aspects that involve closure and data transmission should also be part of this step. A good system for dispensing and inventory logs should also include query resolution and comprehensive audit tracing to ensure that drug accountability data is accurate and transparent. Returns depot workers should be able to offer a link to destruction certification once the trial is concluded, indicating that the site, monitor, depot, and destruction facility information is fully integrated into comprehensive drug accountability criteria.
Rapid Market Growth Due to Covid-19 Pandemic
The clinical trial supply market has grown rapidly because to the COVID-19 issue. In clinical trials around the world the demand for a coronavirus vaccination has increased. Millions of people worldwide must be vaccinated, but tests must be finished before. This condition resulted in an improvement in trends in the supply of clinical trials. In clinical trials, not only vaccinations are being studied but also COVID-19 medications and their symptoms. This will be a major driver in the market for clinical trials.
The major players operating in the clinical trial supplies market are Catalent, Inc., Parexel, Biocair, Thermo Fisher Scientific Inc, Piramal Pharma Solutions, UDG Healthcare PLC, Eurofins Scientific SE, Marken (A UPS Company), PCI Pharma Services, Liveo Research, Lonza, SIRO Clinpharm, KLIFO, Clinigen Group Plc, Ancillare, N-SIDE, ADAllen Pharma, Rubicon Research Pvt S.A., Seveillar Clinical Supplies Services, Myonex, AmerisourceBergen Corporation, DHL, Endpoint Clinical, Coghlan Group, Sharp Corporation. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.